Sustained release dexamethasone

Sustained release dexamethasone is a specialized drug delivery formulation of dexamethasone, a potent corticosteroid with high glucocorticoid activity and minimal mineralocorticoid activity[4]. This formulation is designed to provide controlled release of dexamethasone over an extended period, typically up to 30 days, depending on the specific product[6][9]. ## Formulations and Products There are several sustained release dexamethasone products available or in development: 1. **DEXTENZA®** - An FDA-approved intracanalicular insert that delivers 0.4mg of dexamethasone over 30 days for treating ocular inflammation following ophthalmic surgery[5][6]. It uses a polyethylene glycol (PEG) hydrogel technology with micronized dexamethasone particles conjugated with fluorescein[6]. 2. **DEXYCU®** - Another FDA-approved sustained-release dexamethasone formulation indicated for the same purpose as DEXTENZA®[5]. 3. **Ozurdex®** - A 0.7mg dexamethasone intravitreal implant used for treating macular edema resulting from retinal vein occlusion, diabetic retinopathy, and uveitis or Irvine-Gass syndrome[9]. ## Mechanism of Action Dexamethasone is a highly potent corticosteroid, approximately six times more potent than prednisone[4]. Its mechanism of action involves: - Binding to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory signals[7] - Reducing vasodilation and permeability of capillaries[10] - Decreasing leukocyte migration to sites of inflammation[7] - Inhibiting neutrophil apoptosis and demargination[7] - Inhibiting phospholipase A2, which decreases the formation of arachidonic acid derivatives[7] - Inhibiting NF-Kappa B and other inflammatory transcription factors[7] - Promoting anti-inflammatory genes like interleukin-10[7] In the context of cerebral edema, dexamethasone is believed to either reduce the expression of vascular endothelial growth factor (VEGF) or interfere with VEGF's action on target endothelial cells, thereby decreasing vascular permeability[10]. ## Clinical Applications Sustained release dexamethasone formulations have been developed for various clinical applications: - **Ophthalmic use**: Treatment of ocular inflammation following cataract surgery and other ophthalmic procedures[5][6] - **Macular edema**: Treatment of persistent macular edema resulting from retinal vein occlusion, diabetic retinopathy, and uveitis or Irvine-Gass syndrome[9] - **Tissue engineering**: 3D-printed scaffolds containing sustained release dexamethasone for immunomodulation and tissue regeneration applications[8] ## Pharmacokinetics The sustained release formulations are designed to provide controlled drug delivery over extended periods: - DEXTENZA® provides up to 30 days of drug delivery without preservatives or the need for removal[6] - The release profile typically shows sustained release for 7-15 days before tapering to complete release by day 28[6] - The hydrogel component swells when in contact with tear film, conforming to the anatomical structure and releasing dexamethasone as the hydrogel degrades[6] ## Advantages The sustained release formulations offer several advantages over traditional dexamethasone administration: - Controlled drug release at a stable rate over an extended period[9] - Potentially lower rate of adverse events[9] - Elimination of the need for patient compliance with frequent dosing regimens[6] - Tapering profile similar to most topical regimens, which can help avoid the potential risk of rebound inflammation associated with sudden corticosteroid cessation[6]